SAFETY DATA SHEET



1. Identification

Product identifier TAFINLAR CAPSULES AND PLACEBO

Other means of identification

TAFINLAR CAPSULES 50 MG * TAFINLAR CAPSULES 75 MG * DABRAFENIB CAPSULES * **Synonyms**

GSK2118436B CAPSULES * PLACEBO CAPSULES * DABRAFENIB, FORMULATED PRODUCT

Recommended use Medicinal Product.

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Recommended restrictions

No other uses are advised.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

GlaxoSmithKline US

5 Moore Drive

Research Triangle Park, NC 27709 USA

US General Information (normal business hours): +1-888-825-5249

Email Address: msds@gsk.com Website: www.gsk.com

EMERGENCY PHONE NUMBERS -TRANSPORT EMERGENCIES:

US / International toll call +1 703 527 3887

available 24 hrs/7 days; multi-language response

2. Hazard(s) identification

Classified hazards

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Label elements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Hazard(s) not otherwise classified (HNOC)

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
MICROCRYSTALLINE CELLULOSE	AVICEL PH MICROCRYSTALLINE CELLULOSE ALPHA-CELLULOSE AVICEL PH101 AVICEL PH102 AVICEL PH103 AVICEL PH105 AVICEL PH112 AVICEL PH200 CELLULOSE (8CI9CI) CELLULOSE CRYSTALLINE CELLULOSE, FOOD GRADE	9004-34-6	65.8
PREGELATINIZED STARCH	CRYSTALLINE CELLULOSE	9005-25-8	0 - 99.5

Material name: TAFINLAR CAPSULES AND PLACEBO

132625 Version #: 14 Revision date: 06-03-2015 Issue date: 01-20-2014

Chemical name	Common name and synonyms	CAS number	%
DABRAFENIB MESYLATE	GSK2118436B N-{3-[5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1- DIMETHYLETHYL)-1,3-THIAZOL-4-YL]-2- FLUOROPHENYL}-2,6- DIFLUOROBENZENESULFONAMIDE, METHANESULFONATE, (1:1)	1195768-06-9	0 - 35
MAGNESIUM STEARATE	STEARIC ACID, MAGNESIUM SALT MAGNESIUM DISTEARATE DIBASIC MAGNESIUM STEARATE MAGNESIUM DISTEARATE, PURE	557-04-0	< 1
SILICON DIOXIDE COLLOIDAL		7631-86-9	0.25

^{*}Designates that a specific chemical identity and/or percentage of composition has been withheld as a trade secret.

4. First-aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Skin contact

Get medical attention if symptoms occur.

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. Eye contact

Prolonged exposure may cause chronic effects.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control center immediately. Do not induce vomiting without

advice from poison control center.

Most important

symptoms/effects, acute and

delaved

Indication of immediate medical attention and special

treatment needed

General information

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control

information centre.

In the case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media Unsuitable extinguishing

media

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

None known.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment

and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

Specific methods

equipment/instructions

Move containers from fire area if you can do so without risk.

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions. protective equipment and emergency procedures

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water. For waste disposal, see section 13 of the SDS.

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Inform

Environmental precautions appropriate managerial or supervisory personnel of all environmental releases.

7. Handling and storage

Precautions for safe handling Avoid prolonged exposure. Use personal protective equipment as required. Avoid release to the environment.

SDS US

Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

0

GSK Components	Туре	Value	Note
DABRAFENIB MESYLATE (CAS 1195768-06-9)	8 HR TWA	20 mcg/m3	REPRODUCTIVE HAZARD, CARCINOGEN
(6/16 1100/00 00 0)	OHC	3	REPRODUCTIVE HAZARD, CARCINOGEN
US. OSHA Table Z-1 Limits Components	for Air Contaminants (29 CFR 1910.100 Type	00) Value	Form
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	PEL	5 mg/m3	Respirable fraction.
PREGELATINIZED	PEL	15 mg/m3 5 mg/m3	Total dust. Respirable fraction.
STARCH (CAS 9005-25-8)	*D 4040 4000)	15 mg/m3	Total dust.
US. OSHA Table Z-3 (29 CF Components	Type	Value	
SILICON DIOXIDE COLLOIDAL (CAS 7631-86-9)	TWA	0.8 mg/m3	
·		20 mppcf	
US. ACGIH Threshold Limit Components	t Values Type	Value	
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	TWA	10 mg/m3	
PREGELATINIZED STARCH (CAS 9005-25-8)	TWA	10 mg/m3	
US. NIOSH: Pocket Guide t	o Chemical Hazards		
Components	Туре	Value	Form
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	TWA	5 mg/m3	Respirable.
		10 mg/m3	Total
PREGELATINIZED STARCH (CAS 9005-25-8)	TWA	5 mg/m3	Respirable.
SILICON DIOXIDE COLLOIDAL (CAS 7631-86-9)	TWA	10 mg/m3 6 mg/m3	Total
ogical limit values	No biological exposure limits noted for	the ingredient(s).	
ropriate engineering trols	General ventilation normally adequate. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.		
vidual protection measures Eye/face protection	s, such as personal protective equipment Not normally needed. If contact is likely		ields are recommended.
Skin protection			

Not normally needed. For prolonged or repeated skin contact use suitable protective gloves.

Not normally needed. Wear suitable protective clothing as protection against splashing or

Material name: TAFINLAR CAPSULES AND PLACEBO

Hand protection

Other

SDS US

contamination.

Respiratory protection

No personal respiratory protective equipment normally required. When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Use a NIOSH/MSHA approved respirator if there is a risk of exposure to dust/fume at levels exceeding the exposure limits.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. An occupational/industrial hygiene monitoring method has been developed for this material.

9. Physical and chemical properties

Appearance

Physical state
Form
Capsule.
Color
Not available.
Odor threshold
PH
Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressureNot available.Vapor densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperatureNot available.Decomposition temperatureNot available.ViscosityNot available.

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability

Material is stable under normal conditions.

Possibility of hazardous

Hazardous polymerization does not occur.

reactions

Conditions to avoid

Contact with incompatible materials. Heat, flames and sparks.

Incompatible materials Strong oxidizing agents. Fluorine.

Material name: TAFINLAR CAPSULES AND PLACEBO

SDS US

Hazardous decomposition

products

None known. Irritating and/or toxic fumes and gases may be emitted upon the products

decomposition.

11. Toxicological information

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Inhalation of dusts may cause respiratory irritation.

Skin contact Health injuries are not known or expected under normal use. May be irritating to the skin.

Eye contact Health injuries are not known or expected under normal use.

Ingestion Health injuries are not known or expected under normal use. May be harmful if swallowed.

However, ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to the physical, chemical and toxicological characteristics

Prolonged exposure may cause chronic effects.

Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use. May be harmful if swallowed.

Components Species Test Results

DABRAFENIB MESYLATE (CAS 1195768-06-9)

Acute Oral

LD Rat > 1000 mg/kg Micronucleus study

Subchronic

Oral

LD Rat > 400 mg/kg/day 13 week study

NOAEL Rat < 20 mg/kg/day 13 week study

MAGNESIUM STEARATE (CAS 557-04-0)

Acute Oral

LD50 Rat > 2000 mg/kg

MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)

<u>Acute</u>

Dermal

LD50 Rabbit > 2000 mg/kg

Oral

LD50 Rat > 2000 mg/kg

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Corrosivity

DABRAFENIB MESYLATE Reconstituted Human Epidermis (RHE)

Result: Negative; not considered a significant irritant;

GSK2118436A (free base) tested

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE

Serious eye damage/eye

Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Eve

irritation

DABRAFENIB MESYLATE Reconstituted Human Corneal Epithelium (HCE)

Result: Negative; not likely to be a severe irritant;

GSK2118436A (free base) tested

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days

Respiratory or skin sensitization

Respiratory sensitization Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Material name: TAFINLAR CAPSULES AND PLACEBO
132625 Version #: 14 Revision date: 06-03-2015 Issue date: 01-20-2014

^{*} Estimates for product may be based on additional component data not shown.

Skin sensitization Health injuries are not known or expected under normal use.

Sensitization

DABRAFENIB MESYLATE Local lymph node assay, Maximum test concentration 50%;

vehicle DMF; GSK2118436A tested

Result: Negative Species: Mouse SAR / QSAR Result: Negative

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic. Health injuries are not known or expected under normal use.

Mutagenicity

DABRAFENIB MESYLATE Ames Assay, GLP assay; GSK2118436A (free base) tested

Result: Negative

Ames Assay, GLP assay; GSK2118436B tested

Result: Negative

Micronucleus Assay, GLP assay; tested to MTD of 1000

mg/kg (oral); GSK2118436A (free base) tested

Result: Negative Species: Rat

Mouse Lymphoma Cell (L5178Y) Assay, GLP assay;

GSK2118436A (free base) tested

Result: Negative

SAR / QSAR, DEREK, Lhasa, UK

Result: Negative

Contains a material (dabrafenib) classified as a carcinogen by external agencies. High Carcinogenicity

concentrations or doses administered over an extended period of time were required to produce

adverse effects.

DABRAFENIB MESYLATE Clinical observation, In cancer patients ingestion of

GSK2118436, like other BRAF inhibitors, leads to appearance

of squamous cell skin carcinoma.

SAR / QSAR Result: Negative

IARC Monographs. Overall Evaluation of Carcinogenicity

SILICON DIOXIDE COLLOIDAL (CAS 7631-86-9) 3 Not classifiable as to carcinogenicity to humans.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Contains components which have been classified as: Suspected of damaging fertility or the Reproductive toxicity

unborn child.

Reproductivity

DABRAFENIB MESYLATE Female Fertility / Early Embryonic & Embryo-foetal

Development

Result: Maternal toxicity and decreased corpora lutea, no other fertility effects; foetal lethality, cardiac and thymic defects plus foetal adverse effects noted at lower doses: dose = 300 mg/kg/day; GSK2118436A (free base) tested

Species: Rat

Female Fertility / Early Embryonic & Embryo-foetal

Development

Result: Maternal toxicity, no fertility effects; delayed foetal skeletal development and reduced foetal weight; dose >/= 20

mg/kg/day; GSK2118436A (free base) tested

Species: Rat

Specific target organ toxicity -

single exposure

Not assigned.

Specific target organ toxicity -

repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Not likely, due to the form of the product. **Aspiration hazard**

Prolonged inhalation may be harmful. May cause damage to organs through prolonged or **Chronic effects**

repeated exposure.

Further information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects.

DABRAFENIB MESYLATE 3T3 Cell / Neutral Red Uptake Assay, Potential phototoxicity

Result: Positive

Material name: TAFINLAR CAPSULES AND PLACEBO

12 Ecological information

14	4. E	COI	ogical	IIIIOII	mation

Ecotoxicity

Contains a substance which causes risk of hazardous effects to the environment.

Components		Species	Test Results
DABRAFENIB MESYLAT	E (CAS 1195768-0	06-9)	
Aquatic			
Acute			
Activated Sludge Respiration	IC50	Residential sludge	> 370.3 mg/l, 3 hours OECD 209
	NOEC	Residential sludge	370.3 mg/l, 3 hours
Algae	EC50	Green algae (Pseudokirchnereilla subcapitata)	0.33 mg/l, 72 hours Measured, OECD 202
	NOEC	Green algae (Pseudokirchnereilla subcapitata)	0.26 mg/l, 72 hours
Chronic			
Crustacea	LOEC	Water flea (Daphnia magna)	> 0.12 mg/l, 21 days semi-static test conditions, OECD 211
	NOEC	Water flea (Daphnia magna)	0.12 mg/l, 21 days
Fish	Growth test LOEC	Fathead minnow (Juvenile Pimephales promelas)	3.09 mg/l, 28 days Flow-through test, OECD 210
	Growth test NOEC	Fathead minnow (Juvenile Pimephales promelas)	1.74 mg/l, 28 days
Other	LOEC	Chironomid (Chironomus riparius)	189.6 mg/l, 28 days Measured, OECD 209
	NOEC	Chironomid (Chironomus riparius)	75.84 mg/l, 28 days
MAGNESIUM STEARATI	E (CAS 557-04-0)		
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
SILICON DIOXIDE COLL	OIDAL (CAS 7631-	-86-9)	
Aquatic			
Acute			
Algae	EC50	Green algae (Selenastrum capricornutum)	440 mg/l, 72 hours
	NOEC	Green algae (Selenastrum capricornutum)	60 mg/l, 72 hours
Crustacea	EC50	Water flea (Daphnia magna)	> 10000 mg/l, 24 hours Static test
Fish	EC50	Common carp (Juvenile Cyprinus carpio)	> 10000 mg/l, 72 hours
		Zebra fish (Adult Brachydanio rerio)	5000 mg/l, 96 hours Static test
Microtox	EC50	Microtox	8700 mg/l, 15 minutes
rsistence and degradabili	ity		

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Percent degradation (Aerobic biodegradation-inherent)

DABRAFENIB MESYLATE 0 %, 28 days OECD 301B, CO2 Evolution, ultimate

biodegradation, Activated sludge

81 %, 28 days OECD 301B, CO2 Evolution, primary

degradation, Activated sludge

MAGNESIUM STEARATE 77 %, 28 days BOD

Material name: TAFINLAR CAPSULES AND PLACEBO 132625 Version #: 14 Revision date: 06-03-2015 Issue date: 01-20-2014 Biodegradability

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

Bioaccumulative potential

Partition coefficient n-octanol / water (log Kow)

DABRAFENIB MESYLATE 3.38 (measured at pH 7)

Bioconcentration factor (BCF)

DABRAFENIB MESYLATE 3.98 - 4.38 OECD 305, Measured

Species: Rainbow trout (Adult Oncorhyncus mykiss)

MAGNESIUM STEARATE > 9999 Estimated

Mobility in soil

Adsorption

Sludge/biomass distribution coefficient - log Kd

DABRAFENIB MESYLATE
Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5.86 Estimated

Mobility in general

Distribution

Octanol/water distribution coefficient log DOW

DABRAFENIB MESYLATE -0.17, pH 9

3.23 Measured., pH 5

3.38, pH 7

2.93, pH 7

Other adverse effects Not available.

13. Disposal considerations

Disposal instructionsCollect and reclaim or dispose in sealed containers at licensed waste disposal site. Dispose in

accordance with all applicable regulations.

Hazardous waste codeThe waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

UN number UN3077

UN proper shipping name Environmentally hazardous substances, solid, n.o.s. (DABRAFENIB CAPSULES)

Transport hazard class(es)

Class 9
Subsidiary risk Label(s) 9
Packing group III
Environmental hazards

Marine pollutant Yes

Special precautions for user Not available.

Special provisions 8, 146, 335, A112, B54, IB8, IP3, N20, T1, TP33

Packaging exceptions 155
Packaging non bulk 213
Packaging bulk 240

IATA

UN number UN3077

UN proper shipping name Environmentally hazardous substance, solid, n.o.s. (DABRAFENIB CAPSULES)

Transport hazard class(es) 9
Subsidiary class(es) Packaging group ||||

Environmental hazards No. Labels required 9 ERG Code 9L

Special precautions for user Not available.

Other information

Cargo aircraft only Allowed.
Passenger & cargo Allowed.

IMDG

UN number UN3077

UN proper shipping name Transport hazard class(es) ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (DABRAFENIB CAPSULES)

Class 9
Subsidiary risk Label(s) 9
Packing group III
Environmental hazards

Marine pollutant Yes
EmS F-A, S-F
Special precautions for user Not available.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

DOT: IATA: IMDG



Marine pollutant



General information

Classifications are for the material when offered for transport as fully regulated. Depending on the specific transport details (Ship-From/Ship To locations, quantities being shipped, type of packaging and mode of transport) it may be possible to ship this material in a manner other than fully regulated. (One example is IATA Limited or Excepted Quantity. There are others.) Be sure to review all regulatory agency packaging instructions and special provisions, referenced in this section, to identify options applicable to the specifics of your shipment.

15. Regulatory information

US federal regulations

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - Yes

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous

No

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulations

US. California Controlled Substances. CA Department of Justice (California Health and Safety Code Section 11100)

Not listed.

US. Massachusetts RTK - Substance List

MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6) PREGELATINIZED STARCH (CAS 9005-25-8)

SILICON DIOXIDE COLLOIDAL (CAS 7631-86-9)

US. New Jersey Worker and Community Right-to-Know Act

MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6) SILICON DIOXIDE COLLOIDAL (CAS 7631-86-9)

US. Pennsylvania Worker and Community Right-to-Know Law

MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)

PREGELATINIZED STARCH (CAS 9005-25-8)

SILICON DIOXIDE COLLOIDAL (CAS 7631-86-9)

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No

Country(s) or region Inventory name On inventory (yes/no)*

United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)
A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing

16. Other information, including date of preparation or last revision

 Issue date
 01-20-2014

 Revision date
 06-03-2015

Version # 14

country(s).

Further information HMIS® is a registered trade and service mark of the NPCA. Refer to NFPA 654, Standard for the

Prevention of Fire and Dust Explosions from the Manufacturing, Processing, and Handling of

Combustible Particulate Solids, for safe handling.

HMIS® ratings Health: 3*

Flammability: 1 Physical hazard: 0

NFPA ratings Health: 3

Flammability: 1 Instability: 0

References GSK Hazard Determination

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Revision Information Product and Company Identification: Synonyms

Hazard(s) identification: Hazard(s) not otherwise classified (HNOC)

Composition / Information on Ingredients: Undisclosed Ingredient Statement

Handling and storage: Precautions for safe handling

Toxicological information: Carcinogenicity
Toxicological information: Further information
Toxicological information: Reproductive toxicity

Regulatory Information: United States

Material name: TAFINLAR CAPSULES AND PLACEBO